Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Burton Eisenberg, Margaret von Mehren, Charles D. Blanke et al.|Journal of Surgical Oncology|2008Cited by 419